US Delta-9 THC Markets And German Medical Cannabis Synergize Tilray’s Potential

Summary:

• Tilray Brands has expanded its US (Beer / Delta-9 THC) and German operations (Medical Cannabis).
• The company reported improved financial performance for Q1-2025 and showed a good outlook for the rest of 2025.
• Tilray stock is up 25% over the last week, but down 36% over the last year.
• The cannabis sector still suffers from weak investor sentiment and uncertainty.
• I continue my rating of a Hold on TLRY stock and recommend that investors watch the company and sector.

Tilray Brands Overview

Tilray Brands (NASDAQ:TLRY) recently reported growth and expansion of its operating segments during Q1-2025. The company is also showing improved quarterly financial performance, including improved net loss and increasing gross profit. The company’s current synergies will increase

Analyst’s Disclosure: I/we have a beneficial long position in the shares of TLRY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.